# LINC01614: A Potential Therapeutic Target in Astrocytoma Progression

## TL;DR

This study explores how LINC01614, a long noncoding RNA, promotes astrocytoma growth and identifies it as a potential new treatment target.

## Contribution

The study reveals LINC01614's role in astrocytoma progression via miR-128 sponging and its link to the RAS/Map kinase pathway.

## Key findings

- LINC01614 upregulation promotes astrocytoma cell proliferation and invasion.
- LINC01614 may act as a miR-128 sponge, influencing the RAS/Map kinase signaling pathway.
- Targeting LINC01614 or modulating miR-128 could offer new therapeutic strategies for astrocytoma.

## Abstract

Astrocytomas are aggressive brain tumours with limited treatment options, making the identification of novel therapeutic targets crucial. Long noncoding RNAs (lncRNAs) have emerged as key regulators of gene expression and have been implicated in various cancers, including astrocytoma. LINC01614 is a lncRNA that has been found to be upregulated in astrocytoma, suggesting its potential role in tumour progression. In this study, we investigated the functional role of LINC01614 in astrocytoma and its interaction with miR‐128, a known regulator of the RAS/Map kinase signalling pathway. Through in vitro experimental assays, we demonstrated that LINC01614 upregulation promotes astrocytoma cell proliferation and invasion, potentially through the sponging of miR‐128. Furthermore, in silico analysis revealed potential binding sites of miR‐128 within the RAS/Map kinase signalling pathway, suggesting a regulatory role for miR‐128 in this pathway. Our findings provide novel insights into the molecular mechanisms underlying astrocytoma progression and highlight the potential of LINC01614 as a therapeutic target. Targeting LINC01614 or modulating miR‐128 expression may offer new therapeutic strategies for astrocytoma treatment. Additionally, our in silico analysis provides a foundation for further exploration of the regulatory network involving LINC01614, miR‐128 and the RAS/Map kinase signalling pathway. Overall, this study sheds light on the intricate regulatory network in astrocytoma and presents promising avenues for the development of targeted therapies for this devastating disease.